Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357526 | 1.00 | PPIA (0.33) | PPIAMALT1P2RX7GPR119NR1H2 | |
| SCHEMBL29356913 | 0.86 | ALOX5 (0.40) | — | |
| SCHEMBL19742587 | 0.86 | ALOX5 (0.40) | — | |
| SCHEMBL19742811 | 0.86 | CYP19A1 (0.32) | — | |
| SCHEMBL19754010 | 0.84 | PPIA (0.32) | PPIAP2RX7 | |
| SCHEMBL29355972 | 0.80 | MAPK1 (0.35) | PPIAP2RX7GPR119NR1H2CA1 | |
| SCHEMBL29352527 | 0.80 | CKS1B (0.41) | MALT1CA1CA2CA9CA12 | |
| SCHEMBL29352573 | 0.80 | CYP19A1 (0.33) | CA1CA2CA9CA12CA4 | |
| SCHEMBL19742683 | 0.80 | CKS1B (0.41) | MALT1CA1CA2CA9CA12 | |
| SCHEMBL29355206 | 0.78 | NR1H2 (0.36) | GPR119NR1H2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | PPIA 2047/4885MALT1 677/4885P2RX7 1932/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | PPIA 2047/4885MALT1 677/4885P2RX7 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.